Objectives: Objective: To evaluate the effectiveness of Botulinum Toxin A (BotA) in treating platysma prominence, focusing on non-invasive correction methods for medial and lateral platysma bands.
Introduction: Background: Platysma prominence can significantly affect the aesthetic appearance of the neck, leading to increased interest in non-surgical treatment options. The ageing process contributes to skin laxity, muscle tone loss, and platysma bands' appearance, necessitating effective cosmetic interventions.
Materials / method: The presentation reviews the anatomy of the platysma muscle, its role in facial aesthetics, and the development of a validated assessment scale for platysma bands. It compares different treatment options, including surgical and non-invasive methods, focusing on applying BotA injections for cosmetic improvement.
Results: BotA injections were found to be an effective, non-invasive method for correcting platysma prominence. The treatment showed significant improvement in the appearance of platysma bands within 10-14 days post-injection, with results lasting up to 5 months. Adverse events were infrequent and typically mild.
Conclusion: BotA offers a promising non-surgical alternative for treating platysma prominence, providing significant cosmetic improvement with minimal risk. Future research should focus on optimizing treatment protocols and long-term outcomes.
Declaraciones
¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No
¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No
¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No
¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No
Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.